Table 3. Physical properties of beads for use with DEB-TACE.

DEB	Material	Size availability	Comments
DC/LC Bead	PVA microspheres with sulfonyl group attached	100–300, 300–500, and 700–900 μm	Most well-established DEB, used in the PRECISION V and PRECISION ITALIA studies 48 49
Hepasphere	Sodium acrylate with vinyl alcohol copolymer coat	120–240, 200–400, 400–600, and 600–800 μm	Objective response rate of 67.5% reported according to mRECIST criteria. 85 The cited study includes patients with BCLC A, B, and C HCC
TANDEM	Negatively charged hydrogel core with perfluorinated polymer coating 86	30–50, 60–90, and 75–125 μm	Objective response rate of 63.8% reported according to mRECIST criteria. 87 The cited study did not report patient BCLC stages
LifePearl	Polyethylene glycol	75–125, 150–250, and 350–450 μm	Objective response rate of 85.5% reported according to mRECIST criteria. 88 The cited study includes many patients with BCLC A HCC, so results should be extrapolated to intermediate stage with caution
LUMI Bead	PVA hydrogel with covalently bound iodine moiety. Radiopaque	40–90 and 70–150 μm	Data supporting the use of LUMI Bead in routine clinical practice is currently limited. A small single-arm pilot study (NCT03474354) is currently ongoing 89

Abbreviations: BCLC, Barcelona Clinic Liver Cancer; cTACE, conventional transarterial chemoembolization; DEB-TACE, drug-eluting bead TACE; HCC, hepatocellular carcinoma; PVA, polyvinyl alcohol; TTP, time to tumor progression.